ClinicalTrials.gov
ClinicalTrials.gov Menu

Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02559648
Recruitment Status : Completed
First Posted : September 24, 2015
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
Ersi Voskaridou, Laikon General District Hospital, Athens

Brief Summary:
This is a single-site, randomized, placebo-controlled, double blind phase 2b clinical trial. Patients with Thalassemia will participate in this study and will be treated with Denosumab or placebo. The effect of Denosumab on lumbar spine BMD in patients with Thalassemia Major and Osteoporosis will be evaluated as compared with control (placebo) at 12 months.

Condition or disease Intervention/treatment Phase
Thalassemia Major Osteoporosis Drug: Denosumab Drug: Placebo Phase 2

Detailed Description:

This is a single-site, randomized, placebo-controlled, double blind phase 2b clinical trial. Patients with Thalassemia and Bone Mass Density (BMD) T-score between -2.5 and - 4.0 in at least one of the examined sites will participate in this study and will be treated with Denosumab or placebo.

Patients will be assigned into two (2) treatment groups:

  • In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180).
  • In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180) (Appendix I and Appendix II).

Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.

The effect of Denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated. Also the effect on femoral neck and wrist bone BMD, on markers of bone remodeling and the safety profile will be evaluated as well. All subjects will receive a subcutaneous injection of Denosumab or placebo administered by a health care professional on days 0 and 180 (±3).


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Efficacy of Denosumab in Patients With Thalassemia Major and Osteoporosis: A Randomized, Placebo-controlled, Single-site, Double Blind Phase 2b Clinical Trial
Actual Study Start Date : September 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Denosumab

Arm Intervention/treatment
Active Comparator: Denosumab
In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
Drug: Denosumab

Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.

The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.

Other Name: Prolia

Placebo Comparator: Placebo
In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
Drug: Placebo

Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.

The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated.





Primary Outcome Measures :
  1. The percent change in the lumbar spine BMD [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. The percent change in BMD of the total hip and femoral neck [ Time Frame: 12 months ]
  2. The percent change in BMD at the distal third radius [ Time Frame: 12 months ]
  3. The percent change in serum C-Termina Telopeptide (sCTX) at Month 3 post injection [ Time Frame: 3 months ]

Other Outcome Measures:
  1. Adverse event incidence by system organ class and preferred term [ Time Frame: 12 months ]
  2. Changes from baseline in safety laboratory analytes [ Time Frame: 12 months ]
  3. Changes in vital signs at each visit [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults (>30 years of age) described as skeletally mature subjects
  • Thalassemia Major
  • Low BMD (T-score <-2.5) in one of the 3 studied sites (lumbar spine, femoral neck, wrist).
  • Have signed the informed consent form (consent should be taken before any study-specific procedure is performed).

Exclusion Criteria:

  • BMD T-score < -4.0 in one of the 2 studied sites (lumbar spine, femoral neck).
  • Previous administration of denosumab from clinical trials or others (e.g. commercial use).
  • Current participation in another clinical trial or having received any investigational product within the last 3 months.
  • Impaired renal function as determined by an estimated glomerular filtration rate (eGFR) of ≤ 30 mL/min (using the Chronic Kidney Disease-Epidemiology, ((CKD-EPI) formula).
  • Patients with sickle cell disease.
  • Known to have a liver failure or chronic hepatic disease e.g. cirrhosis, chronic hepatitis; or elevated transaminases defined as Alanine Transaminase (ALT) and/or Aspartate Transaminase (AST) > 2 fold the upper limit of normal laboratory range.
  • Heart failure (NYHA above 2).
  • Patients with life expectancy of less than one year.
  • Subject refuses to use a reliable contraceptive method (oral contraceptives, progesterone implants, intrauterine device, condoms) throughout the study by women of childbearing potential. Women of childbearing potential agree to use 2 highly effective forms of contraception and to continue this practice for 7 months after last injection of study medication.
  • Pregnancy, planning a pregnancy or currently lactating
  • Severe concurrent illness which in the investigator's opinion may confound patient evaluation, e.g. malignancy (except basal cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.
  • Known alcohol or drug abuse or any other condition associated with poor compliance
  • Patients that have received oral bisphosphonates within 6 months of study enrollment or intravenous bisphosphonates, fluoride and strontium ranelate within 1 year of study enrollment.
  • Parathormone (PTH), PTH derivatives, teriparatide, odanacatib, anabolic steroids, testosterone, glucocorticosteroids (> 5 mg/day of prednisone equivalent for > 10 days), systemic hormone-replacement therapy, selective estrogen receptor modulators (SERMs), raloxifene, tibolone, calcitonin or calcitriol use within the last 6 weeks.
  • Evidence of hyper- or hypothyroidism; patients with an abnormal Thyroid stimulating hormone (TSH) level on thyroid treatment (patients on stable thyroid treatment with a normal TSH allowed); current hyper- or hypoparathyroidism; current hyper or hypocalcemia (hypocalcemia based on albumin adjusted serum calcium < 8.5 mg/dL); vitamin D deficiency (25-hydroxy Vitamin D level < 12 ng/mL; if repeat 12-20 ng/mL after repletion, subject will be allowed); rheumatoid arthritis; Paget's disease; bone disease that would interfere with interpretation of findings.
  • Known sensitivity to mammalian cell-derived drug products.
  • History of any Solid Organ or Bone Marrow Transplant
  • History of osteonecrosis of the jaw, and/or recent tooth extraction or other dental surgery; or planned invasive dental work during the study.
  • Intolerance to calcium supplements.
  • Malabsorption syndrome; severe malabsorption including Celiac disease, Short Bowel Syndrome, Crohn's disease, Previous Gastric Bypass.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02559648


Locations
Greece
General Hospital of Athens "Laikon"
Athens, Attica, Greece, 11526
Sponsors and Collaborators
Ersi Voskaridou
Investigators
Principal Investigator: Ersi Voskaridou, Doctor General Hospital of Athens "Laikon"

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ersi Voskaridou, Director of National center of Thalassaemia and Haemoglobinopathies of Laikon General Hospital of Athens, Laikon General District Hospital, Athens
ClinicalTrials.gov Identifier: NCT02559648     History of Changes
Other Study ID Numbers: EL-THOS-001
2014-000931-18 ( EudraCT Number )
First Posted: September 24, 2015    Key Record Dates
Last Update Posted: August 9, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Osteoporosis
Thalassemia
beta-Thalassemia
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
Denosumab
Bone Density Conservation Agents
Physiological Effects of Drugs